Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits

Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits

Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are two determinants in the aetiology of T2D, and...

Full description

Bibliographic Details
Main Authors:	Daisuke Yabe, Hitoshi Kuwata, Masahiro Iwasaki, Yutaka Seino
Format:	Article
Language:	English
Published:	European Medical Journal 2015-11-01
Series:	European Medical Journal Diabetes
Subjects:	dipeptidyl peptidase 4 (DPP-4) inhibitor East Asian glucagon-like peptide-1 receptor agonist (GLP-1RA) incretin Type 2 diabetes mellitus (T2D)
Online Access:	http://emjreviews.com/wp-content/uploads/Why-Are-Incretin-Based-Therapies-More-Efficient-in-East-Asians..-Perspectives-From-the-Pathophysiology-of-Type-2-Diabetes-and-East-Asian-Dietary-Habits.pdf

Similar Items

Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2018-11-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
by: Suk Chon, et al.
Published: (2016-04-01)

Role of Incretin Axis in Inflammatory Bowel Disease
by: Lihua Duan, et al.
Published: (2017-12-01)

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
by: Lili Liu, et al.
Published: (2019-03-01)

Inflammation and Incretins
by: Amitabh Hatwal
Published: (2012-01-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

Incretin response in Asian type 2 diabetes: Are Indians different?
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2
by: Félix Andrés Reyes Sanamé, et al.

Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018-12-01)

Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption
by: Hideki Kitaura, et al.
Published: (2021-06-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-05-01)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-02-01)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01)

Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01)

Las incretinas: nueva alternativa terapéutica para el control glucometabólico de la diabetes mellitus de tipo 2 Incretins: a new therapeutic alternative for the glycometabolic control of the type 2 diabetes mellitus
by: Yaily Lazo Roblejo, et al.
Published: (2012-03-01)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
by: Kugler AJ, et al.
Published: (2018-05-01)

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
by: Daiji Kawanami, et al.
Published: (2016-07-01)

Nephroprotective properties of glucose-lowering drugs
by: Elena V. Pokrovskaya, et al.
Published: (2019-04-01)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
by: Geke Aline Boer, et al.
Published: (2020-12-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01)

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas
by: Giuseppe Roberto, et al.
Published: (2019-02-01)

The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes.
by: Gorana Mirošević, et al.
Published: (2017-09-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Dietary supplementation of rutin and rutin-rich buckwheat elevates endogenous glucagon-like peptide 1 levels to facilitate glycemic control in type 2 diabetic mice
by: Lin-Chien Lee, et al.
Published: (2021-10-01)

The Origin and Understanding of the Incretin Concept
by: Jens F. Rehfeld
Published: (2018-07-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01)

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
by: Dandan Zhao, et al.
Published: (2018-03-01)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
by: Ira Gantz, et al.
Published: (2017-09-01)